Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Saved in:
| Title: | Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. |
|---|---|
| Authors: | Sanyal AJ; Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA., Kowdley KV; Department of Gastroenterology and Hepatology, Elson Floyd College of Medicine, Spokane, Washington, USA., Reau NS; Department of Medicine, Rush University, Chicago, Illinois, USA., Pyrsopoulos NT; Rutgers New Jersey Medical School, Newark, New Jersey, USA., Allen C; Salix Pharmaceuticals, Bridgewater, New Jersey, USA., Heimanson Z; Salix Pharmaceuticals, Bridgewater, New Jersey, USA., Bajaj JS; Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA.; Central Virginia Veterans Healthcare System, Richmond, Virginia, USA. |
| Source: | Hepatology communications [Hepatol Commun] 2024 May 10; Vol. 8 (6). Date of Electronic Publication: 2024 May 10 (Print Publication: 2024). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Clinical Trial, Phase IV |
| Journal Info: | Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
